Payment overview · 2025
General Payments
$839.50
60 reported records · 15 companies
Healthcare provider profile · identity verified
Ryan P Buffalo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HEBER SPRINGS, AR · NPI 1356330666
Verified facts
What the public records show
CMS Open Payments records show Ryan P Buffalo, M.D. received $839.50 in general payments during 2025 across 60 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.25 | 23.3% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $181.66 | 21.6% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.71 | 17.1% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.73 | 6.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.61 | 6.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.63 | 5.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.13 | 4.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $32.34 | 3.9% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.79 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.51 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.76 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.74 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.39 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.71 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.54 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $839.50 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $195.25 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $181.66 | 23 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $118.08 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $113.38 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $93.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.73 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.13 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $9.48 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 87 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 258 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
258 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 889 | 261 |
| Levothyroxine Sodium | Levothyroxine Sodium | 680 | 188 |
| Gabapentin | Gabapentin | 657 | 180 |
| Omeprazole | Omeprazole | 615 | 171 |
| Losartan Potassium | Losartan Potassium | 562 | 186 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 168 |
| Lisinopril | Lisinopril | 547 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 488 | 155 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 475 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 131 |
| Hydrochlorothiazide | Hydrochlorothiazide | 445 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 362 | 114 |
| Metformin Hcl | Metformin Hcl | 357 | 113 |
| Trazodone Hcl | Trazodone Hcl | 322 | 90 |
| Meloxicam | Meloxicam | 299 | 102 |
| Furosemide | Furosemide | 281 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 92 |
| Tramadol Hcl | Tramadol Hcl | 261 | 74 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 258 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 240 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 228 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 60 |
| Alprazolam | Alprazolam | 210 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 55 |
| Doxycycline Hyclate | Doxycycline Hyclate | 196 | 162 |
| Lorazepam | Lorazepam | 196 | 47 |
| Sertraline Hcl | Sertraline Hcl | 184 | 53 |
| Allopurinol | Allopurinol | 182 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 60 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 167 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 47 |
| Methylprednisolone | Methylprednisolone | 158 | 139 |
| Potassium Chloride | Potassium Chloride | 156 | 53 |
| Memantine Hcl | Memantine Hcl | 154 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 49 |
| Prednisone | Prednisone | 151 | 90 |
| Amitriptyline Hcl | Amitriptyline Hcl | 150 | 41 |
| Carvedilol | Carvedilol | 147 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 144 | 47 |
| Eliquis | Apixaban | 141 | 32 |
| Clonazepam | Clonazepam | 139 | 27 |
| Finasteride | Finasteride | 138 | 34 |
| Aripiprazole | Aripiprazole | 137 | 26 |
| Simvastatin | Simvastatin | 135 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 39 |
| Famotidine | Famotidine | 131 | 40 |
| Ventolin Hfa | Albuterol Sulfate | 130 | 34 |
| Montelukast Sodium | Montelukast Sodium | 129 | 40 |
| Ozempic | Semaglutide | 126 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 120 | 27 |
| Buspirone Hcl | Buspirone Hcl | 119 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 35 |
| Atenolol | Atenolol | 117 | 36 |
| Bupropion Xl | Bupropion Hcl | 117 | 29 |
| Pregabalin | Pregabalin | 116 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 112 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 32 |
| Azithromycin | Azithromycin | 100 | 82 |
| Cefdinir | Cefdinir | 97 | 78 |
| Donepezil Hcl | Donepezil Hcl | 97 | 25 |
| Glipizide Er | Glipizide | 91 | 25 |
| Ondansetron Odt | Ondansetron | 89 | 35 |
| Warfarin Sodium | Warfarin Sodium | 88 | 19 |
| Jardiance | Empagliflozin | 87 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 19 |
| Spironolactone | Spironolactone | 82 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 44 |
| Primidone | Primidone | 78 | 19 |
| Ezetimibe | Ezetimibe | 76 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 17 |
| Mirtazapine | Mirtazapine | 74 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 71 | 18 |
| Metformin Hcl Er | Metformin Hcl | 69 | 23 |
| Dexamethasone | Dexamethasone | 68 | 63 |
| Temazepam | Temazepam | 68 | 18 |
| Cephalexin | Cephalexin | 67 | 59 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 18 |
| Sucralfate | Sucralfate | 64 | 19 |
| Linzess | Linaclotide | 62 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 40 |
| Nystatin | Nystatin | 61 | 28 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Estradiol | Estradiol | 58 | 20 |
| Eszopiclone | Eszopiclone | 57 | 15 |
| Topiramate | Topiramate | 57 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 42 |
| Glipizide | Glipizide | 53 | 16 |
| Ibuprofen | Ibuprofen | 52 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 14 |
| Alendronate Sodium | Alendronate Sodium | 51 | 11 |
| Celecoxib | Celecoxib | 51 | 14 |
| Diazepam | Diazepam | 51 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 12 |
| Promethazine Hcl | Promethazine Hcl | 49 | 14 |
| Baclofen | Baclofen | 48 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 19 |
| Naproxen | Naproxen | 47 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 47 | 11 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 34 |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 16 |
| Glimepiride | Glimepiride | 35 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Mometasone Furoate | Mometasone Furoate | 33 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 21 |
| Valacyclovir | Valacyclovir Hcl | 33 | 19 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 24 |
| Fluconazole | Fluconazole | 29 | 21 |
| Methocarbamol | Methocarbamol | 29 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | 12 |
| Valsartan | Valsartan | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 23 | 23 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Zaleplon | Zaleplon | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 13 |
| Megestrol Acetate | Megestrol Acetate | 15 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $839.50 · 60 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, LOREEV XR, MOUNJARO, NURTEC ODT, Ohtuvayre, PREVNAR 20, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error